mkdir -p /home/daytona/workspace/pih-presentation && ls /home/daytona/workspace/…

~/pih-presentation/pih.js

const pptxgen = require("pptxgenjs");
const prs = new pptxgen();

prs.layout = "LAYOUT_16x9";
prs.title = "Pregnancy Induced Hypertension";
prs.author = "Medical Education";

// ── Color palette ──────────────────────────────────────────────
const DARK_BG   = "0D1B2A";   // deep navy – title / section dividers
const MID_BG    = "1B3A5C";   // steel blue
const ACCENT    = "E63946";   // vivid red – danger/warning emphasis
const GOLD      = "F4A261";   // warm amber – headings on dark bg
const WHITE     = "FFFFFF";
const LIGHT_BG  = "F0F4F8";   // slide body bg
const TEXT_DARK = "1A1A2E";   // near-black body text
const TEAL      = "2A9D8F";   // secondary accent
const LIGHT_TXT = "D0E4F7";   // muted light text on dark bg

// ── Helper: section divider slide ─────────────────────────────
function sectionDivider(title, subtitle) {
  const sl = prs.addSlide();
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: DARK_BG } });
  // Accent bar
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 2.4, w: 10, h: 0.08, fill: { color: ACCENT } });
  sl.addText(title, {
    x: 0.8, y: 1.3, w: 8.4, h: 1,
    fontSize: 36, bold: true, color: GOLD, align: "center", fontFace: "Calibri"
  });
  if (subtitle) {
    sl.addText(subtitle, {
      x: 1, y: 2.8, w: 8, h: 0.8,
      fontSize: 18, color: LIGHT_TXT, align: "center", fontFace: "Calibri"
    });
  }
  return sl;
}

// ── Helper: body slide ────────────────────────────────────────
function bodySlide(title, bullets, opts = {}) {
  const sl = prs.addSlide();
  // Background
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: LIGHT_BG } });
  // Title bar
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.95, fill: { color: MID_BG } });
  // Left accent strip
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 0.12, h: 5.625, fill: { color: ACCENT } });
  sl.addText(title, {
    x: 0.22, y: 0.08, w: 9.6, h: 0.78,
    fontSize: 22, bold: true, color: WHITE, valign: "middle", fontFace: "Calibri", margin: 0
  });
  // Bullets
  const items = bullets.map((b, i) => {
    if (b.sub) {
      return { text: b.text, options: { bullet: { indent: 25 }, fontSize: 14, color: "555577", breakLine: i < bullets.length - 1 } };
    }
    return { text: b.text || b, options: { bullet: { color: ACCENT, code: "2022" }, fontSize: opts.fontSize || 15.5, color: TEXT_DARK, bold: b.bold || false, breakLine: i < bullets.length - 1 } };
  });
  sl.addText(items, {
    x: 0.35, y: 1.05, w: opts.w || 9.4, h: opts.h || 4.35,
    valign: "top", fontFace: "Calibri", lineSpacingMultiple: 1.15
  });
  return sl;
}

// ── Helper: two-column slide ──────────────────────────────────
function twoColSlide(title, leftItems, rightItems, leftHead, rightHead) {
  const sl = prs.addSlide();
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: LIGHT_BG } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.95, fill: { color: MID_BG } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 0.12, h: 5.625, fill: { color: ACCENT } });
  sl.addText(title, {
    x: 0.22, y: 0.08, w: 9.6, h: 0.78,
    fontSize: 22, bold: true, color: WHITE, valign: "middle", fontFace: "Calibri", margin: 0
  });
  // Column divider
  sl.addShape(prs.ShapeType.rect, { x: 5.08, y: 1.0, w: 0.04, h: 4.4, fill: { color: TEAL } });
  // Left heading
  if (leftHead) {
    sl.addShape(prs.ShapeType.rect, { x: 0.25, y: 1.0, w: 4.6, h: 0.42, fill: { color: TEAL } });
    sl.addText(leftHead, { x: 0.3, y: 1.02, w: 4.5, h: 0.38, fontSize: 14, bold: true, color: WHITE, fontFace: "Calibri", margin: 0 });
  }
  if (rightHead) {
    sl.addShape(prs.ShapeType.rect, { x: 5.2, y: 1.0, w: 4.6, h: 0.42, fill: { color: MID_BG } });
    sl.addText(rightHead, { x: 5.25, y: 1.02, w: 4.5, h: 0.38, fontSize: 14, bold: true, color: WHITE, fontFace: "Calibri", margin: 0 });
  }
  const mkItems = (arr) => arr.map((b, i) => ({
    text: b.text || b,
    options: { bullet: { color: ACCENT, code: "2022" }, fontSize: 13.5, color: TEXT_DARK, breakLine: i < arr.length - 1 }
  }));
  sl.addText(mkItems(leftItems), { x: 0.25, y: leftHead ? 1.5 : 1.1, w: 4.7, h: leftHead ? 3.9 : 4.3, valign: "top", fontFace: "Calibri", lineSpacingMultiple: 1.15 });
  sl.addText(mkItems(rightItems), { x: 5.2, y: rightHead ? 1.5 : 1.1, w: 4.6, h: rightHead ? 3.9 : 4.3, valign: "top", fontFace: "Calibri", lineSpacingMultiple: 1.15 });
  return sl;
}

// ╔══════════════════════════════════════════════════════════════╗
// ║  SLIDE 1 — TITLE                                            ║
// ╚══════════════════════════════════════════════════════════════╝
{
  const sl = prs.addSlide();
  // Full dark background
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: DARK_BG } });
  // Top decorative bar
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.18, fill: { color: ACCENT } });
  // Bottom decorative bar
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 5.44, w: 10, h: 0.18, fill: { color: ACCENT } });
  // Side accent
  sl.addShape(prs.ShapeType.rect, { x: 0.3, y: 0.18, w: 0.1, h: 5.265, fill: { color: TEAL } });

  sl.addText("PREGNANCY INDUCED", {
    x: 0.6, y: 0.8, w: 8.8, h: 1.0,
    fontSize: 42, bold: true, color: WHITE, align: "center", fontFace: "Calibri", charSpacing: 3
  });
  sl.addText("HYPERTENSION", {
    x: 0.6, y: 1.65, w: 8.8, h: 1.1,
    fontSize: 52, bold: true, color: GOLD, align: "center", fontFace: "Calibri", charSpacing: 4
  });
  // Subtitle line
  sl.addShape(prs.ShapeType.rect, { x: 2.5, y: 2.88, w: 5, h: 0.06, fill: { color: ACCENT } });
  sl.addText("Preeclampsia · Eclampsia · HELLP Syndrome", {
    x: 0.6, y: 3.0, w: 8.8, h: 0.6,
    fontSize: 19, color: LIGHT_TXT, align: "center", fontFace: "Calibri", italic: true
  });
  sl.addText("Pathophysiology · Diagnosis · Management", {
    x: 0.6, y: 3.55, w: 8.8, h: 0.5,
    fontSize: 15, color: LIGHT_TXT, align: "center", fontFace: "Calibri"
  });
  sl.addText("Sources: Creasy & Resnik's Maternal-Fetal Medicine · Robbins Pathology · Guyton & Hall · Goodman & Gilman", {
    x: 0.6, y: 4.8, w: 8.8, h: 0.45,
    fontSize: 10, color: "8899AA", align: "center", fontFace: "Calibri", italic: true
  });
}

// ╔══════════════════════════════════════════════════════════════╗
// ║  SLIDE 2 — OUTLINE                                          ║
// ╚══════════════════════════════════════════════════════════════╝
bodySlide("Presentation Outline", [
  { text: "1.  Introduction & Definition" },
  { text: "2.  ACOG Classification of Hypertensive Disorders of Pregnancy" },
  { text: "3.  Epidemiology & Risk Factors" },
  { text: "4.  Pathogenesis – Placental & Vascular Mechanisms" },
  { text: "5.  Pathophysiologic Changes (Multi-Organ)" },
  { text: "6.  Clinical Features & Diagnostic Criteria" },
  { text: "7.  Laboratory Findings & Investigations" },
  { text: "8.  HELLP Syndrome" },
  { text: "9.  Eclampsia" },
  { text: "10. Management – Antihypertensives & MgSO4" },
  { text: "11. Delivery Timing & Definitive Treatment" },
  { text: "12. Prevention & Prognosis" },
  { text: "13. Summary" },
]);

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 1 — INTRODUCTION                                   ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 1", "Introduction & Definition");

bodySlide("What is Pregnancy Induced Hypertension?", [
  { text: "Hypertension affects up to 10% of pregnant women in the United States" },
  { text: "Hypertensive disorders of pregnancy (HDP) = ~85 per 1,000 deliveries in the US" },
  { text: "PIH is a disorder unique to pregnancy – completely reversible after delivery" },
  { text: "Characterized by poor perfusion of vital organs including the fetoplacental unit" },
  { text: "NOT merely an unmasking of pre-existing chronic hypertension" },
  { text: "Umbrella term includes: gestational hypertension, preeclampsia, eclampsia, HELLP" },
  { text: "Generally presents after 20 weeks of gestation" },
  { text: "New-onset hypertension with or without proteinuria >300 mg/24 h" },
]);

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 2 — CLASSIFICATION                                 ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 2", "ACOG Classification of Hypertensive Disorders");

{
  const sl = prs.addSlide();
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: LIGHT_BG } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.95, fill: { color: MID_BG } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 0.12, h: 5.625, fill: { color: ACCENT } });
  sl.addText("ACOG Classification (2020 Practice Bulletin #222)", {
    x: 0.22, y: 0.08, w: 9.6, h: 0.78,
    fontSize: 20, bold: true, color: WHITE, valign: "middle", fontFace: "Calibri", margin: 0
  });

  const rows = [
    [{ text: "Category", options: { bold: true, color: WHITE, fill: { color: MID_BG } } },
     { text: "Timing / BP Criteria", options: { bold: true, color: WHITE, fill: { color: MID_BG } } },
     { text: "Key Features", options: { bold: true, color: WHITE, fill: { color: MID_BG } } }],
    [{ text: "Gestational HTN" }, { text: "New BP ≥140/90 after 20 wks (×2, ≥4 hr apart)" }, { text: "No proteinuria; resolves postpartum" }],
    [{ text: "Preeclampsia" }, { text: "Gestational HTN + proteinuria >0.3 g/24 h OR end-organ damage" }, { text: "Thrombocytopenia, renal/hepatic impairment, pulmonary edema, headache" }],
    [{ text: "Preeclampsia\nwith Severe Features" }, { text: "SBP ≥160 or DBP ≥110 mmHg" }, { text: "Platelets <100×10⁹/L; Cr >1.1 mg/dL; AST/ALT ≥2× ULN; pulmonary edema; visual/neuro symptoms" }],
    [{ text: "Eclampsia" }, { text: "Preeclampsia + new-onset seizures" }, { text: "Can occur antepartum, intrapartum, or ≤48 h postpartum" }],
    [{ text: "HELLP Syndrome" }, { text: "Variant of severe preeclampsia" }, { text: "Hemolysis + Elevated Liver enzymes + Low Platelets" }],
    [{ text: "Chronic HTN" }, { text: "Hypertension before pregnancy or before 20 wks" }, { text: "Does not resolve postpartum" }],
    [{ text: "Chronic HTN + Superimposed\nPreeclampsia" }, { text: "Preeclampsia in a woman with chronic HTN" }, { text: "Worse prognosis than either condition alone" }],
  ];

  sl.addTable(rows, {
    x: 0.2, y: 1.0, w: 9.6, h: 4.4,
    colW: [1.8, 3.6, 4.2],
    border: { color: "C0C8D8", pt: 0.5 },
    align: "left",
    fontFace: "Calibri",
    fontSize: 11,
    color: TEXT_DARK,
    autoPage: false,
  });
}

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 3 — EPIDEMIOLOGY & RISK FACTORS                    ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 3", "Epidemiology & Risk Factors");

{
  const sl = prs.addSlide();
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: LIGHT_BG } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.95, fill: { color: MID_BG } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 0.12, h: 5.625, fill: { color: ACCENT } });
  sl.addText("Epidemiology", {
    x: 0.22, y: 0.08, w: 9.6, h: 0.78,
    fontSize: 22, bold: true, color: WHITE, valign: "middle", fontFace: "Calibri", margin: 0
  });

  // Stat boxes
  const stats = [
    { val: "~5%", lbl: "Preeclampsia prevalence" },
    { val: "85/1000", lbl: "HDP rate (US deliveries)" },
    { val: "32.3%", lbl: "Attributable fraction: nulliparity" },
    { val: "25%", lbl: "Risk with chronic HTN" },
    { val: "20%", lbl: "Risk in pregestational diabetes" },
    { val: "~20%", lbl: "Eclampsia >48h postpartum" },
  ];
  stats.forEach((s, i) => {
    const col = i % 3;
    const row = Math.floor(i / 3);
    const x = 0.3 + col * 3.2;
    const y = 1.1 + row * 2.1;
    sl.addShape(prs.ShapeType.rect, { x, y, w: 3.0, h: 1.7, fill: { color: MID_BG }, line: { color: TEAL, pt: 1.5 } });
    sl.addText(s.val, { x, y: y + 0.15, w: 3.0, h: 0.8, fontSize: 30, bold: true, color: GOLD, align: "center", fontFace: "Calibri" });
    sl.addText(s.lbl, { x, y: y + 0.9, w: 3.0, h: 0.65, fontSize: 12, color: LIGHT_TXT, align: "center", fontFace: "Calibri" });
  });
}

twoColSlide(
  "Risk Factors for Preeclampsia",
  [
    "Nulliparity (greatest population-attributable risk)",
    "Prior preeclampsia in previous pregnancy",
    "Chronic hypertension",
    "Chronic renal failure (with or without DM)",
    "Pregestational diabetes mellitus",
    "Antiphospholipid syndrome",
    "Connective tissue disorders (SLE)",
    "Extremes of maternal age",
  ],
  [
    "Multiple gestation / IVF",
    "Family history of preeclampsia",
    "Non-White race (linked to severity)",
    "Hydatidiform mole",
    "Hydrops fetalis",
    "Obesity / metabolic syndrome",
    "First pregnancy with new partner",
    "Low socioeconomic status (for eclampsia)",
  ],
  "Maternal / Medical Factors",
  "Obstetric / Other Factors"
);

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 4 — PATHOGENESIS                                   ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 4", "Pathogenesis – Placental & Vascular Mechanisms");

bodySlide("Normal vs. Preeclamptic Placentation", [
  { text: "NORMAL PREGNANCY:", bold: true },
  { text: "Trophoblasts invade spiral arteries of uterine endometrium", sub: true },
  { text: "Musculoelastic walls remodeled → wide vascular sinusoids (low resistance)", sub: true },
  { text: "High-flow, low-resistance uteroplacental circulation established", sub: true },
  { text: "PREECLAMPSIA:", bold: true },
  { text: "Trophoblast invasion is IMPAIRED – reason still unclear", sub: true },
  { text: "Musculoelastic walls retained → channels remain narrow", sub: true },
  { text: "Reduced uteroplacental blood flow → placental hypoxia & ischemia", sub: true },
  { text: "Placenta releases antiangiogenic factors: sFlt-1 (anti-VEGF) & soluble endoglin (anti-TGF-β)", sub: true },
  { text: "→ Endothelial dysfunction, vascular hyperreactivity, end-organ microangiopathy", sub: true },
], { fontSize: 14 });

bodySlide("Molecular Mechanisms of Endothelial Dysfunction", [
  { text: "Prostacyclin (PGI₂) ↓ — vasodilator and anti-aggregant" },
  { text: "Thromboxane A₂ (TXA₂) ↑ — vasoconstrictor and pro-aggregant → net vasoconstriction" },
  { text: "Nitric oxide (NO) production ↓ → impaired vasodilation" },
  { text: "Soluble Flt-1 (sFlt-1) ↑ → binds and neutralizes VEGF and PlGF in circulation" },
  { text: "Soluble endoglin ↑ → antagonizes TGF-β signaling" },
  { text: "Inflammatory cytokines (TNF-α, IL-6) ↑ → systemic endothelial injury" },
  { text: "Endothelin-1 ↑ → potent vasoconstrictor (though at sub-threshold levels in vivo)" },
  { text: "Exaggerated sensitivity to angiotensin II → small doses cause large BP spikes" },
  { text: "Net result: Hypertension + proteinuria + multi-organ ischemia" },
]);

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 5 — PATHOPHYSIOLOGY (MULTI-ORGAN)                  ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 5", "Pathophysiologic Changes – Multi-Organ Involvement");

twoColSlide(
  "Cardiovascular & Renal Changes",
  [
    "Cardiac output falls to pre-pregnancy levels with onset of preeclampsia",
    "Systemic vascular resistance ↑↑ → drives hypertension",
    "Arteriolar narrowing (retina, kidney, nail bed, conjunctiva)",
    "Increased sensitivity to all endogenous pressors (angiotensin II ×2.5 more sensitive)",
    "Plasma volume contraction despite sodium/water retention",
    "Paradoxical ↑ ANF with ↓ plasma renin → suggests effective circulating volume ↑ relatively",
  ],
  [
    "Glomerular filtration rate (GFR) ↓ – opposite to normal pregnancy",
    "Renal blood flow ↓",
    "Glomeruloendotheliosis – hallmark renal lesion (swollen glomerular endothelium)",
    "Proteinuria >300 mg/24 h (diagnostic criterion)",
    "Hyperuricemia – early sensitive marker (uric acid clearance ↓ before GFR falls)",
    "Serum creatinine ↑ in severe disease",
    "Sodium retention → edema, weight gain",
    "Total body sodium ↑ despite concentrated urine",
  ],
  "Cardiovascular",
  "Renal"
);

twoColSlide(
  "Hepatic, CNS & Hematologic Changes",
  [
    "Hepatic: Periportal fibrin deposition & necrosis",
    "AST and ALT ↑↑ → poor prognosis",
    "Hepatic capsular distension → RUQ pain, tenderness",
    "Risk of hepatic rupture (rare but catastrophic)",
    "HELLP: Microangiopathic hemolytic anemia + elevated liver enzymes + low platelets",
    "Placental: Infarcts, retroplacental hemorrhage, ischemic villous changes",
    "Acute atherosis of decidual vessels",
  ],
  [
    "CNS: Cerebral edema, vasospasm, microinfarcts",
    "Posterior reversible encephalopathy syndrome (PRES) on MRI",
    "Symptoms: Headache, visual disturbances, altered mental status",
    "Seizures = eclampsia",
    "Hematologic: Thrombocytopenia (platelet consumption)",
    "DIC in severe cases (rare but life-threatening)",
    "Coagulation factor changes, ↓ antithrombin III",
    "Hypercoagulability from endothelial dysfunction",
  ],
  "Hepatic & Placental",
  "CNS & Hematologic"
);

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 6 — CLINICAL FEATURES                              ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 6", "Clinical Features & Diagnostic Criteria");

bodySlide("Clinical Features of Preeclampsia", [
  { text: "Most commonly starts after 34 weeks; earlier with hydatidiform mole or pre-existing disease" },
  { text: "Classic triad: Hypertension + Edema + Proteinuria (edema no longer diagnostic)" },
  { text: "Hypertension: SBP ≥140 OR DBP ≥90 mmHg on two readings ≥4 hours apart" },
  { text: "Severe range: SBP ≥160 OR DBP ≥110 mmHg (can confirm within minutes)" },
  { text: "Edema: Dependent edema common; facial/periorbital edema more concerning" },
  { text: "Rapid weight gain (fluid retention)" },
  { text: "Headache (new-onset, not relieved by analgesics)" },
  { text: "Visual disturbances: Blurring, scotoma, diplopia" },
  { text: "Epigastric or RUQ pain (hepatic capsular distension)" },
  { text: "Signs of severe disease: Pulmonary edema, oliguria, convulsions, coma" },
]);

// Diagnostic criteria table slide
{
  const sl = prs.addSlide();
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: LIGHT_BG } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.95, fill: { color: MID_BG } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 0.12, h: 5.625, fill: { color: ACCENT } });
  sl.addText("Diagnostic Criteria – Severe Features of Preeclampsia", {
    x: 0.22, y: 0.08, w: 9.6, h: 0.78,
    fontSize: 20, bold: true, color: WHITE, valign: "middle", fontFace: "Calibri", margin: 0
  });

  const rows2 = [
    [{ text: "System", options: { bold: true, color: WHITE, fill: { color: DARK_BG } } },
     { text: "Criterion", options: { bold: true, color: WHITE, fill: { color: DARK_BG } } },
     { text: "Threshold", options: { bold: true, color: WHITE, fill: { color: DARK_BG } } }],
    [{ text: "Blood Pressure" }, { text: "Severe range HTN" }, { text: "SBP ≥160 or DBP ≥110 mmHg (×2, ≥4 hr apart)" }],
    [{ text: "Renal" }, { text: "Proteinuria" }, { text: ">0.3 g/24 hr OR protein/creatinine ratio >0.3" }],
    [{ text: "Renal" }, { text: "Renal insufficiency" }, { text: "Cr >1.1 mg/dL or doubling (excl. other causes)" }],
    [{ text: "Hematologic" }, { text: "Thrombocytopenia" }, { text: "Platelets <100 × 10⁹/L" }],
    [{ text: "Hepatic" }, { text: "Impaired liver function" }, { text: "AST/ALT ≥2× ULN + severe RUQ/epigastric pain" }],
    [{ text: "Pulmonary" }, { text: "Pulmonary edema" }, { text: "New onset" }],
    [{ text: "CNS" }, { text: "Neurological symptoms" }, { text: "Headache unrelieved by analgesics; visual disturbances" }],
    [{ text: "Special" }, { text: "HELLP syndrome" }, { text: "Hemolysis + elevated liver enzymes + low platelets" }],
  ];
  sl.addTable(rows2, {
    x: 0.2, y: 1.0, w: 9.6, h: 4.45,
    colW: [1.6, 3.0, 5.0],
    border: { color: "C0C8D8", pt: 0.5 },
    align: "left",
    fontFace: "Calibri",
    fontSize: 12,
    color: TEXT_DARK,
  });
}

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 7 — LABORATORY INVESTIGATIONS                      ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 7", "Laboratory Findings & Investigations");

bodySlide("Investigations in Preeclampsia", [
  { text: "URINE:", bold: true },
  { text: "24-hr urine protein (>300 mg diagnostic)", sub: true },
  { text: "Spot protein/creatinine ratio >0.3", sub: true },
  { text: "Urine dipstick ≥2+ (if quantitative unavailable)", sub: true },
  { text: "RENAL FUNCTION:", bold: true },
  { text: "Serum uric acid ↑ – early sensitive marker; precedes GFR fall", sub: true },
  { text: "Serum creatinine (↑ in severe disease)", sub: true },
  { text: "24-hr creatinine clearance (decreased in most severe cases)", sub: true },
  { text: "HEPATIC & HEMATOLOGIC:", bold: true },
  { text: "AST, ALT (elevated = poor prognosis)", sub: true },
  { text: "Full blood count – platelets (↓); RBC morphology (schistocytes in HELLP)", sub: true },
  { text: "Coagulation screen – PT, aPTT, fibrinogen, antithrombin III", sub: true },
  { text: "LDH ↑ (hemolysis), serum bilirubin ↑", sub: true },
  { text: "IMAGING:", bold: true },
  { text: "MRI brain in eclampsia – PRES pattern (white matter edema)", sub: true },
  { text: "Fetal ultrasound – IUGR assessment, biophysical profile, Doppler", sub: true },
], { fontSize: 13.5 });

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 8 — HELLP SYNDROME                                 ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 8", "HELLP Syndrome");

bodySlide("HELLP Syndrome – Overview", [
  { text: "HELLP = Hemolysis + Elevated Liver enzymes + Low Platelets" },
  { text: "Occurs in ~10% of women with severe preeclampsia" },
  { text: "A microangiopathic process driven by endothelial dysfunction" },
  { text: "Hemolysis: Microangiopathic hemolytic anemia – schistocytes on blood film" },
  { text: "Elevated liver enzymes: AST/ALT ≥2× ULN; LDH ↑" },
  { text: "Low platelets: <100 × 10⁹/L from platelet consumption in microthrombi" },
  { text: "Can occur without hypertension or proteinuria in up to 20% of cases" },
  { text: "Associated with risk of: DIC, renal failure, abruptio placentae, hepatic rupture" },
  { text: "Management: Urgent delivery; corticosteroids may improve platelet counts transiently" },
  { text: "Prognosis: Maternal mortality ~1-3%; perinatal mortality significantly elevated" },
]);

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 9 — ECLAMPSIA                                      ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 9", "Eclampsia");

bodySlide("Eclampsia – Features & Management", [
  { text: "Definition: New-onset tonic-clonic convulsions in the setting of preeclampsia" },
  { text: "Can occur: Antepartum (most common), intrapartum, or ≤48 h postpartum" },
  { text: "~20% of eclampsia episodes occur >48 hours after delivery" },
  { text: "Pathology: Cerebral vasospasm, edema, microinfarcts, petechial hemorrhages" },
  { text: "PRES (Posterior Reversible Encephalopathy) seen on MRI" },
  { text: "MgSO₄ is the drug of choice – seizure prophylaxis AND treatment" },
  { text: "MgSO₄ mechanism: Blocks NMDA receptors; vasodilation; ↓ cerebral irritability" },
  { text: "Loading dose: 4-6 g IV over 15-20 min; maintenance 1-2 g/hr infusion" },
  { text: "Monitor: Knee reflexes (loss precedes respiratory depression), urine output, Mg levels" },
  { text: "Antidote for Mg toxicity: Calcium gluconate 10 mL of 10% IV" },
  { text: "Renal function and hepatic function impaired in eclampsia" },
  { text: "Proteinuria and hypertension usually disappear within 1-2 weeks post delivery" },
]);

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 10 — MANAGEMENT                                    ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 10", "Pharmacologic Management");

bodySlide("Antihypertensive Therapy in Pregnancy", [
  { text: "WHEN TO TREAT: DBP >105 mmHg OR SBP >160 mmHg (ACOG consensus)" },
  { text: "DRUGS TO AVOID:", bold: true },
  { text: "ACE inhibitors → fetal renal dysgenesis, oligohydramnios, IUFD", sub: true },
  { text: "Angiotensin receptor blockers (ARBs) → same fetal toxicity profile", sub: true },
  { text: "PREFERRED ORAL AGENTS:", bold: true },
  { text: "Alpha-methyldopa (250 mg BD) – former FDA category B; centrally acting; first-line oral", sub: true },
  { text: "Labetalol (100 mg BD) – combined α1/β blocker; reasonable safety data", sub: true },
  { text: "Nifedipine (30 mg OD slow-release) – calcium channel blocker; effective", sub: true },
  { text: "ACUTE/SEVERE HYPERTENSION (inpatient):", bold: true },
  { text: "Hydralazine: 5-10 mg IV/IM; repeat every 20 min based on response", sub: true },
  { text: "Labetalol: 20 mg IV; escalate to 40 mg at 10 min if inadequate", sub: true },
  { text: "IV nifedipine or nicardipine also used in some settings", sub: true },
], { fontSize: 13.5 });

bodySlide("Magnesium Sulfate – Seizure Prophylaxis & Treatment", [
  { text: "INDICATIONS:", bold: true },
  { text: "All severe preeclampsia with CNS manifestations (headache, visual disturbance, altered mental status)", sub: true },
  { text: "All cases of eclampsia (treatment of ongoing seizures)", sub: true },
  { text: "Postpartum women with persistent CNS manifestations (≥48 h watch)", sub: true },
  { text: "DOSING:", bold: true },
  { text: "Loading: 4-6 g in 100 mL normal saline IV over 15-20 min", sub: true },
  { text: "Maintenance: 1-2 g/hr IV infusion", sub: true },
  { text: "MONITORING:", bold: true },
  { text: "Patellar reflex present (loss at ~7 mEq/L, respiratory depression at ~10 mEq/L)", sub: true },
  { text: "Urine output ≥25 mL/hr (Mg excreted renally)", sub: true },
  { text: "Respiratory rate ≥12/min", sub: true },
  { text: "Serum Mg level (therapeutic range 4-7 mEq/L)", sub: true },
  { text: "ANTIDOTE: Calcium gluconate 10 mL of 10% solution IV slowly", sub: true },
  { text: "Documented efficacy with no adverse fetal effects (unlike other anticonvulsants)", sub: true },
], { fontSize: 13.5 });

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 11 — DELIVERY & DEFINITIVE TREATMENT               ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 11", "Delivery Timing & Definitive Treatment");

bodySlide("Delivery – The Definitive Treatment", [
  { text: "ONLY definitive treatment is delivery of the fetus and placenta" },
  { text: "With severe preeclampsia + end-organ damage + mature fetus → IMMEDIATE delivery" },
  { text: "Threshold: ≥34 weeks – generally recommend delivery" },
  { text: "Before 34 weeks: Balance risks of prematurity vs. continued preeclampsia" },
  { text: "Expectant management (hospitalization + pharmacotherapy) may allow fetal lung maturation" },
  { text: "Corticosteroids (betamethasone): Stimulate fetal lung maturation if preterm delivery anticipated" },
  { text: "Mode of delivery: Vaginal preferred if cervix favorable; cesarean for obstetric indications" },
  { text: "Postpartum: Continue MgSO₄ for ≥24-48 h after delivery" },
  { text: "Antihypertensives continued postpartum until BP normalizes" },
  { text: "Hypertension and proteinuria usually resolve within 1-2 weeks after delivery" },
  { text: "Rare: Persistent hypertension >12 wks postpartum → investigate for chronic HTN" },
]);

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 12 — PREVENTION & PROGNOSIS                        ║
// ╚══════════════════════════════════════════════════════════════╝
sectionDivider("SECTION 12", "Prevention & Prognosis");

twoColSlide(
  "Prevention & Long-term Outcomes",
  [
    "Low-dose aspirin (81 mg/day from 12-16 wks) → reduces risk in high-risk women",
    "Calcium supplementation (1.5-2 g/day) in low-calcium intake populations",
    "Antioxidant vitamins (C, E) – NOT proven effective in large RCTs",
    "Salt restriction / diuretics do NOT prevent preeclampsia",
    "Preconception optimization: Control chronic HTN, DM, obesity",
    "Close antenatal surveillance for at-risk women",
    "Early screening: UtA Doppler + PlGF + PAPP-A at 11-14 wks",
  ],
  [
    "Favorable: Most cases resolve completely after delivery",
    "Increased lifetime cardiovascular risk after preeclampsia (2-4× risk of CVD)",
    "Higher risk of hypertension, ischemic heart disease, stroke in later life",
    "Recurrence risk: 15-20% in subsequent pregnancies",
    "Higher recurrence with onset <28 wks or severe features",
    "Eclampsia fatality: Now rare with early recognition and MgSO₄",
    "Major cause of maternal mortality globally (especially in LMICs)",
  ],
  "Prevention Strategies",
  "Prognosis & Long-term Risk"
);

// ╔══════════════════════════════════════════════════════════════╗
// ║  SECTION 13 — SUMMARY                                       ║
// ╚══════════════════════════════════════════════════════════════╝
{
  const sl = prs.addSlide();
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: DARK_BG } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.08, fill: { color: ACCENT } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 5.545, w: 10, h: 0.08, fill: { color: ACCENT } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 0.12, h: 5.625, fill: { color: TEAL } });
  sl.addText("Key Takeaways", {
    x: 0.3, y: 0.12, w: 9.4, h: 0.75,
    fontSize: 26, bold: true, color: GOLD, fontFace: "Calibri", align: "center"
  });
  const pts = [
    "PIH is unique to pregnancy – caused by defective trophoblast invasion of spiral arteries",
    "Central mechanism: Placental ischemia → antiangiogenic factors (sFlt-1, endoglin) → systemic endothelial dysfunction",
    "Diagnosis requires BP ≥140/90 after 20 wks + proteinuria OR end-organ damage",
    "Severe features demand urgent delivery or intensive management",
    "MgSO₄ is the standard for seizure prevention and treatment in eclampsia",
    "Avoid ACE inhibitors and ARBs – teratogenic and fetotoxic",
    "HELLP syndrome affects ~10% of severe preeclampsia – life-threatening",
    "Delivery is the ONLY definitive treatment; balance maturity vs. maternal risk",
    "Aspirin (low-dose) from first trimester reduces risk in high-risk patients",
    "Survivors have increased lifetime cardiovascular risk – long-term follow-up needed",
  ];
  const items = pts.map((p, i) => ({
    text: p,
    options: { bullet: { color: GOLD, code: "25CF" }, fontSize: 13.5, color: WHITE, breakLine: i < pts.length - 1 }
  }));
  sl.addText(items, {
    x: 0.3, y: 1.0, w: 9.4, h: 4.4,
    valign: "top", fontFace: "Calibri", lineSpacingMultiple: 1.2
  });
}

// Final Thank You slide
{
  const sl = prs.addSlide();
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: DARK_BG } });
  sl.addShape(prs.ShapeType.rect, { x: 0, y: 2.5, w: 10, h: 0.06, fill: { color: ACCENT } });
  sl.addText("Thank You", {
    x: 0, y: 1.5, w: 10, h: 1.2,
    fontSize: 52, bold: true, color: GOLD, align: "center", fontFace: "Calibri"
  });
  sl.addText("Questions & Discussion", {
    x: 0, y: 2.75, w: 10, h: 0.7,
    fontSize: 22, color: LIGHT_TXT, align: "center", fontFace: "Calibri", italic: true
  });
  sl.addText("Sources: Creasy & Resnik's Maternal-Fetal Medicine (9780323828499) · Robbins & Kumar Basic Pathology ·\nGuyton & Hall Medical Physiology · Goodman & Gilman Pharmacology · Braunwald's Heart Disease", {
    x: 0.5, y: 3.8, w: 9.0, h: 0.9,
    fontSize: 10, color: "8899AA", align: "center", fontFace: "Calibri", italic: true
  });
}

// Write file
prs.writeFile({ fileName: "/home/daytona/workspace/pih-presentation/Pregnancy_Induced_Hypertension.pptx" })
  .then(() => console.log("DONE: Pregnancy_Induced_Hypertension.pptx created"))
  .catch(e => { console.error(e); process.exit(1); });

cd /home/daytona/workspace/pih-presentation && node pih.js

ls -lh /home/daytona/workspace/pih-presentation/